Annual percent change by component in Saskatchewan*
| Route of administration | Component; % change (95% CI) | ||||
|---|---|---|---|---|---|
| Total expenditure per capita | Cancer incidence per capita† | Users per incident case | Prescriptions per use | Cost per prescription | |
| Total | 9.2 (7.2 to 11.2) | 0.2 (−0.3 to 0.6) | 1.9 (1.2 to 2.5) | 2.2 (1.8 to 2.6) | 4.7 (3.5 to 6.0) |
| Oral | 16.5 (13.6 to 19.6) | 0.2 (−0.3 to 0.6) | 2.0 (1.1 to 2.9) | 3.2 (1.8 to 4.6) | 10.6 (7.8 to 13.5) |
| Intravenous/other | 6.7 (4.6 to 8.8) | 0.2 (−0.3 to 0.6) | 2.0 (1.3 to 2.7) | 1.4 (0.7 to 2.1) | 2.9 (1.9 to 4) |
| Oral; cancer site | |||||
| Breast | 10.8 (4.9 to 17.1) | 0.4 (−0.3 to 1.2) | 3.0 (1.3 to 4.7) | 2.0 (−0.3 to 4.2) | 5.3 (−0.2 to 11.0) |
| Colorectum | 6.5 (2.7 to 10.4) | 4.4 (3.0 to 5.8) | 3.2 (0.0 to 6.5) | 8.0 (5.8 to 10.2) | −8.4 (−10.5 to −6.2) |
| Lung | 24.3 (4.0 to 48.5) | 0.3 (−0.7 to 1.3) | 4.0 (1.3 to 6.8) | 0.4 (−1.1 to 2.0) | 19.6 (0.8 to 41.9) |
| Prostate | 31.9 (12.0 to 55.4) | −4.9 (−7.3 to −2.4) | 3.2 (0.9 to 5.4) | 1.4 (−1.6 to 4.5) | 31.6 (12.9 to 53.4) |
| Other | 16.9 (13.0 to 21.0) | 0.2 (−0.8 to 1.2) | 1.2 (0.1 to 2.4) | 4.2 (3.1 to 5.4) | 10.6 (6.6 to 14.6) |
| Intravenous; cancer site | |||||
| Breast | −2.8 (−6.0 to 0.5) | 0.4 (−0.3 to 1.2) | −0.7 (−2.4 to 1.1) | 0.4 (−0.9 to 1.6) | −2.8 (−4.6 to −0.9) |
| Colorectum | 14.0 (7.8 to 20.6) | 4.4 (3.0 to 5.8) | −1.5 (−4.3 to 1.3) | 0.2 (−0.8 to 1.2) | 10.6 (6.8 to 14.6) |
| Lung | 11.8 (8.2 to 15.6) | 0.3 (−0.7 to 1.3) | 1.8 (−0.2 to 3.8) | 1.5 (0.2 to 2.9) | 7.8 (5.7 to 9.9) |
| Prostate | 1.0 (−1.0 to 3.0) | −4.9 (−7.3 to −2.4) | 6.1 (3.1 to 9.1) | 4.1 (2.9 to 5.3) | −3.7 (−5.1 to −2.4) |
| Other | 10.6 (8.8 to 12.4) | 0.2 (−0.8 to 1.2) | 4.1 (3.2 to 5.1) | 1.3 (0.0 to 2.7) | 4.6 (3.0 to 6.1) |
| Oral; patient age, yr | |||||
| < 50 | 14.1 (−11.4 to 46.9) | 1.6 (0.5 to 2.6) | 3.9 (3.0 to 4.9) | 1.9 (0.0 to 3.7) | 5.6 (3.9 to 7.4) |
| 50–59 | 13.5 (−6.5 to 37.9) | −0.7 (−1.9 to 0.6) | 3.5 (1.6 to 5.6) | 3.9 (1.9 to 5.9) | 6.5 (−0.6 to 14.2) |
| 60–69 | 20.3 (3.7 to 39.5) | −1.0 (−1.6 to −0.4) | 4.6 (3.2 to 6.0) | 3.6 (1.7 to 5.5) | 12.1 (9.4 to 14.9) |
| 70–79 | 18.7 (4.2 to 35.2) | 1.0 (0.1 to 1.9) | 0.6 (−0.7 to 2.0) | 2.1 (0.6 to 3.5) | 14.5 (12.7 to 16.3) |
| ≥ 80 | 11.4 (−1.4 to 25.8) | 0.6 (−0.4 to 1.7) | −4.0 (−5.9 to −2.2) | 1.6 (0.0 to 3.2) | 13.8 (8.0 to 19.9) |
| Intravenous; patient age, yr | |||||
| < 50 | 6.3 (−12.1 to 28.6) | 1.6 (0.5 to 2.6) | 0.8 (−0.3 to 1.9) | 3.0 (1.2 to 4.7) | 0.8 (−1.0 to 2.7) |
| 50–59 | 7.4 (−4.3 to 20.4) | −0.7 (−1.9 to 0.6) | 2.8 (1.4 to 4.3) | 2.2 (1.0 to 3.4) | 2.8 (1.6 to 4.0) |
| 60–69 | 6.5 (−1.6 to 15.1) | −1.0 (−1.6 to −0.4) | 2.8 (1.3 to 4.4) | 1.0 (−0.4 to 2.4) | 3.5 (2.5 to 4.5) |
| 70–79 | 8.2 (−1.7 to 19.2) | 1.0 (0.1 to 1.9) | 1.8 (0.9 to 2.8) | 0.6 (−0.9 to 2.2) | 4.5 (3.2 to 5.8) |
| ≥ 80 | 0.5 (−14.0 to 17.5) | 0.6 (−0.4 to 1.7) | 0.9 (−0.6 to 2.3) | −2.3 (−4.6 to 0.1) | 1.2 (−2.1 to 4.7) |